Mats Olof Strömqvist

Vakona is a Swedish company that is developing a new biological drug for the treatment of acne. The drug is based on a bacterial enzyme and has the potential to significantly reduce treatment time and side effects such as skin irritation. The company's research is based on over a decade of work by Dr. Oleg Alexeyev and aims to provide an alternative to the long-term inefficacy of current acne therapies that rely on antibiotics. The company was founded by Oleg Alexeyev and has CEOs Mats Olof Strömqvist and Gabriella Persson.

Omnio Healer AB is a company developing novel drug candidates based on a series of conceptual breakthroughs in inflammation research. This new, pro-inflammatory approach opens up completely new therapeutic strategies for wound healing and anti-infection. The company's lead drug candidate, aimed primarily at otological indications, has achieved promising preclinical results and will enter a clinical development program in late 2010. Since its foundation in 2006 Omnio Healer has assembled a management and development team. This includes scientists within the field, experienced product development professionals and active investors led by Karolinska Development AB, providing access to a network of biotechnology development resources. The company is based in Umeå, Sweden.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.